Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "Q2FY22"

33 News Found

Syngene reports better than expected revenues, margin pressure in Q1FY22: ICICI Direct
News | October 25, 2021

Syngene reports better than expected revenues, margin pressure in Q1FY22: ICICI Direct

Key takeaways of recent quarter & conference call highlights

Domestic growth to the fore as US weakness persists: ICICI Direct
News | October 19, 2021

Domestic growth to the fore as US weakness persists: ICICI Direct

ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report

Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr
Biotech | August 08, 2021

Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr

The company expects revenue growth of 10-15 per cent in the US

Latest Stories

Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr

Sigachi Industries signs MoU with Respilon Group

USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging